

# Saying goodbye and remembering

Richard W McCallum<sup>1,2</sup>

<sup>1</sup>Center for Neurogastroenterology and GI Motility Gastroenterology/Hepatology and Nutrition, Texas Tech University Health Sciences Center, Paul L. Foster School of Medicine, El Paso, Texas, USA  
<sup>2</sup>University of Queensland, Brisbane, Queensland, Australia

**Correspondence to** Richard W McCallum, Internal Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, Texas, USA; richard.mccallum@ttuhsc.edu

Accepted 3 November 2022

Well, colleagues, this will be my last Editorial for the *Journal of Investigative Medicine* (JIM) under the BMJ flag. Beginning in January 2023, JIM will publish under the aegis of a new publisher, SAGE.

For me, the last 3 years as Editor-in-Chief of JIM have been both very exciting and rewarding, and I will briefly summarize some of the highlights and achievements from my tenure.

- 2019: I was appointed EIC mid-year, and per my first editorial,<sup>1</sup> one of my key strategies was to introduce new article types that addressed faculty development, education, mentoring, and careers.
- 2020: In addition to celebrating JIM's 25th anniversary, we introduced a monthly podcast. The first episode featured my personal perspectives on the microbiome field. Since that time, we've published 33 podcasts, with an average of 444 listens per podcast.
- 2021: Submission growth surpassed previous years, showing an increase of 50% from 2016 to 2021. On the heels of the COVID-19 pandemic, JIM published two articles that have generated a great deal of attention, as evidenced by their Altmetrics scores: 'Long COVID-19 following mild SARS-CoV-2 infection: characteristic T cell alterations and response to antihistamines',<sup>2</sup> a research article published in October by Glynne *et al*, and 'COVID-19 reinfection: a rapid systematic review of case reports and case series',<sup>3</sup> a brief report published in May by Wang *et al*. The first of these articles is the highest downloaded article published since JIM began at BMJ.
- 2022: At this writing, the editorial team continues to improve the quality of JIM submissions, as evidenced by an immediate rejection rate of nearly 50% and a decreased acceptance rate for all papers of 28%. Web traffic has grown steadily in the past 5

years and is expected to increase by 20% over 2021, and JIM's 2021 impact factor of 3.301 (announced in June 2022) was a 14% increase over 2020, evidence of the improved quality of the content published in JIM.

I want to take this opportunity to sincerely thank the BMJ team for their 'stewardship' of JIM. Specifically, I am deeply grateful to Kathleen Lyons, head of Portfolio, based in Hoboken, New Jersey (yes, the birthplace of Frank Sinatra); Hannah Martin, based in London, JIM's production editor, who helped us produce and finalize each issue from BMJ; and our great editorial assistant team of Rachel Wright, Chloe Tuck, and Caty Waterfield.

Overall, I say to you, my American Federation for Medical Research (AFMR) colleagues and all our readers and contributors to JIM, in the words of an Australian with a love for cricket, we have had a good 'inning' with BMJ and will always be grateful and appreciative of the ties and relationship between AFMR and BMJ.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None declared.

**Patient consent for publication** Not applicable.

**Provenance and peer review** Commissioned; internally peer reviewed.

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

## REFERENCES

- 1 McCallum RW. Richard W. McCallum, MD: New Editor-in-Chief, *Journal of Investigative Medicine*. *J Investig Med* 2020;68:1–2.
- 2 Glynne P, Tahmasebi N, Gant V, *et al*. Long COVID following mild SARS-CoV-2 infection: characteristic T cell alterations and response to antihistamines. *J Investig Med* 2022;70:61–7.
- 3 Wang J, Kaperak C, Sato T, *et al*. COVID-19 reinfection: a rapid systematic review of case reports and case series. *J Investig Med* 2021;69:1253–5.



**To cite:** McCallum RW. *J Investig Med* 2022;70:1661.